Tienhaara A, Pelliniemi T T
Department of Haematology, Turku University Central Hospital, Finland.
Acta Haematol. 1994;91(2):57-61. doi: 10.1159/000204253.
Multiple myeloma (MM) is a disease of terminally differentiated B lineage cells and thus alterations in circulating B cells may be anticipated. We studied peripheral blood B cells by flow cytometry in 45 untreated MM patients and compared the results to 25 age-matched controls. The total lymphocyte count and the absolute number and percentage of CD20+ cells were significantly decreased in MM patients. Analysis of the relative amounts of CD20+ cells expressing surface immunoglobulin kappa or lambda light chain isotype did not show either clonal B cell excess or light chain isotype suppression. The percentages of CD10+ and CD20+10+ cells were low both in MM patients and in controls. We consider that the CD20+ cells analysed in this study mainly consisted of normal polyclonal B cells. However, the percentage of the CD20+ cells in the peripheral blood of MM patients was a prognostic factor for survival, both as a continuous and as a dichotomized variable.
多发性骨髓瘤（MM）是一种终末分化B淋巴细胞疾病，因此循环B细胞可能会发生改变。我们通过流式细胞术研究了45例未经治疗的MM患者的外周血B细胞，并将结果与25例年龄匹配的对照进行比较。MM患者的总淋巴细胞计数、CD20+细胞的绝对数量和百分比显著降低。对表达表面免疫球蛋白κ或λ轻链同种型的CD20+细胞的相对数量分析未显示克隆性B细胞增多或轻链同种型抑制。MM患者和对照组中CD10+和CD20+10+细胞的百分比均较低。我们认为本研究中分析的CD20+细胞主要由正常多克隆B细胞组成。然而，MM患者外周血中CD20+细胞的百分比无论是作为连续变量还是二分变量，都是生存的一个预后因素。
